出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年5月
NGSベースのRNAシーケンス市場 : 製品とサービス (サンプル調製、プラットフォームと消耗品、サービス、データ分析)、テクノロジー (SBS、SMRT、ナノポア)、用途(De Novo、エピジェネティクス、small RNA)、エンドユーザー、地域別 – 2027年までの世界予測
NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region – Global Forecast to 2027
| ページ数 | 202 |
| 図表数 | 200 |
| 種別 | 英文調査報告書 |
| 価格 |
世界のNGSベースのRNAシーケンス市場は2022年中に25億ドル、2027年までの55億ドルに達し、予測期間内の年平均成長率（CAGR）は17.2％になると予測されています。
MarketsandMarkets（マーケッツアンドマーケッツ）「NGSベースのRNAシーケンス市場 : 製品とサービス (サンプル調製、プラットフォームと消耗品、サービス、データ分析)、テクノロジー (SBS、SMRT、ナノポア)、用途(De Novo、エピジェネティクス、small RNA)、エンドユーザー、地域別 – 2027年までの世界予測 – NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region – Global Forecast to 2027」は世界の次世代シーケンシング（NGS）を用いたRNAシーケンス（RNA-Seq）市場における主要セグメント毎の調査・分析結果を提供します。
Report Overview
The global NGS-based RNA-sequencing market is projected to reach USD 5.5 billion by 2027 from USD 2.5 billion in 2022, at a CAGR of 17.2% during the forecast period.
Growth in the NGS-based RNA-sequencing market is mainly driven by the advantages of RNA sequencing over conventional technologies, the decreasing cost of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine. On the other hand, a lack of qualified specialists, end-user budget constraints in developing countries, and standardization concerns in diagnostic testing are expected to limit the market growth.
“Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period.”
Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.
“Expression profiling analysis applications segment dominated the market in 2021.”
On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.
“North America held the dominant share of the market in 2021.”
Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 45%, Tier 2: 34%, Tier 3: 21%
• By Designation – C-level: 47.0%, D-level: 33.0%, and Others: 20.0%
• By Region – North America: 35%, Europe: 32%, Asia Pacific: 25%, Latin America: 6%, and the Middle East & Africa: 2%
List of Companies Profiled in the Report
o Illumina, Inc. (US)
o Thermo Fisher Scientific, Inc. (US)
o PerkinElmer, Inc. (US)
o QIAGEN N.V. (Netherlands)
o Eurofins Scientific (UK)
o Oxford Nanopore Technologies (UK)
o Agilent Technologies, Inc. (US)
o BGI Group (China)
o GENEWIZ (US)
o Hamilton Company (US)
o NuGEN Technologies (US)
o Psomagen, Inc. (South Korea)
o F. Hoffmann-La Roche AG (Switzerland)
o Takara Bio, Inc. (Japan)
o Pacific Biosciences (US)
o Zymo Research Corporation (US)
o Lucigen Corporation (US)
o Genotypic Technology (India)
o Oxford Gene Technology (UK)
o Becton, Dickinson and Company (US)
Research Coverage:
This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on NGS-based RNA-sequencing offered by the top 20 players in the NGS-based RNA-sequencing market. The report analyses the NGS-based RNA-sequencing market by product & service, technology, application, end user, and region.
• Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various NGS-based RNA-sequencing products and services across key geographic regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-sequencing market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the NGS-based RNA-sequencing market.
目次
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 REGIONAL SCOPE 25
1.3.3 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 26
1.5 STAKEHOLDERS 26
1.6 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY RESEARCH 29
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY RESEARCH 30
2.1.2.1 Key data from primary sources 31
FIGURE 2 BREAKDOWN OF PRIMARIES 31
2.2 MARKET ESTIMATION METHODOLOGY 32
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33
2.2.1 PRODUCT-BASED MARKET ESTIMATION 34
FIGURE 4 PRODUCT-BASED MARKET ESTIMATION 34
2.2.2 APPLICATION-BASED MARKET ESTIMATION 34
FIGURE 5 APPLICATION-BASED MARKET ESTIMATION 35
2.3 PRIMARY RESEARCH VALIDATION 35
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 36
FIGURE 6 DATA TRIANGULATION 36
2.5 STUDY ASSUMPTIONS 36
FIGURE 7 STUDY ASSUMPTIONS 37
2.6 RESEARCH LIMITATIONS 37
3 EXECUTIVE SUMMARY 38
FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION) 38
FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 39
FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 39
FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 40
FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET 41
4 PREMIUM INSIGHTS 42
4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW 42
FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET 42
4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021) 43
FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021 43
4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET 44
FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 44
4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION 45
FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 47
FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
5.2.1 DRIVERS 47
5.2.1.1 Decreasing costs of genome sequencing 47
FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2021 48
5.2.1.2 Advantages of RNA-sequencing over conventional technologies 48
5.2.1.3 Increasing government funding to support genomics projects 49
5.2.1.4 Growing research involving RNA-sequencing 49
5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research 50
TABLE 1 CANCER INCIDENCE, 2020 VS. 2040 50
5.2.1.6 Rapid growth in personalized medicine adoption 51
5.2.2 RESTRAINTS 51
5.2.2.1 Lack of qualified specialists 51
5.2.2.2 End-user budget constraints in developing countries 51
5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing 52
5.2.3 OPPORTUNITIES 52
5.2.3.1 Adoption of blockchain technology and cloud computing 52
5.2.4 CHALLENGES 53
5.2.4.1 Storage and interpretation of sequencing data 53
5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts 53
5.2.4.3 Ethical issues and challenges in testing procedure 54
6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE 55
6.1 INTRODUCTION 56
TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 56
6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES 56
6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH 56
TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 59
6.3 SAMPLE PREPARATION PRODUCTS 59
6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW 59
TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 59
TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 60
TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 60
TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61
TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61
6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW 61
6.3.2.1 Library preparation & target enrichment 61
6.3.2.2 Quality control 62
6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD 62
6.3.3.1 Manual sample preparation 62
6.3.3.2 Microfluidic sample preparation 62
6.3.3.3 Robotic liquid handling sample preparation 62
6.4 RNA-SEQUENCING SERVICES 63
6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND 63
TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 63
TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
6.5 DATA ANALYSIS, STORAGE & MANAGEMENT 65
6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET 65
TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 67
TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 67
TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68
TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68
7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY 69
7.1 INTRODUCTION 70
TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 70
7.2 SEQUENCING BY SYNTHESIS 70
7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME 70
TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 71
TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
7.3 ION SEMICONDUCTOR SEQUENCING 73
7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES 73
TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING 76
7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS 76
TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
7.5 NANOPORE SEQUENCING 79
7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES 79
TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION 83
8.1 INTRODUCTION 84
TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84
8.2 EXPRESSION PROFILING ANALYSIS 84
8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET 84
TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3 SMALL RNA-SEQUENCING 87
8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET 87
TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
8.4 DE NOVO TRANSCRIPTOME ASSEMBLY 89
8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT 89
TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS 92
8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT 92
TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER 96
9.1 INTRODUCTION 97
TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027 (USD MILLION) 97
9.2 RESEARCH & ACADEMIA 97
9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET 97
TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020–2027 (USD MILLION) 98
9.3 HOSPITALS & CLINICS 99
9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET 99
TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 99
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET 100
TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 100
9.5 OTHER END USERS 101
TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 101
10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION 102
10.1 INTRODUCTION 103
TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020–2027(USD MILLION) 103
10.2 NORTH AMERICA 103
FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT 104
TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION) 104
TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 105
TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 105
TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 106
TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION) 106
10.2.1 US 106
10.2.1.1 Favorable funding scenario and growing R&D activity to drive market 106
TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 107
TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 108
TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 108
10.2.2 CANADA 109
10.2.2.1 Government initiatives for genome research to boost market 109
TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 109
TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 110
TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 110
10.3 EUROPE 110
TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION) 111
TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 111
TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 112
TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 112
TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION) 113
10.3.1 GERMANY 113
10.3.1.1 Germany to dominate European market during forecast period 113
TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 114
TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 114
TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 115
10.3.2 UK 115
10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market 115
TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 116
TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 116
TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 117
10.3.3 FRANCE 117
10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth 117
TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 118
TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 118
TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 119
10.3.4 REST OF EUROPE 119
TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 120
TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 120
TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 121
10.4 ASIA PACIFIC 121
FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT 122
TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION) 123
TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 123
TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 124
TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 124
TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION) 125
10.4.1 CHINA 125
10.4.1.1 Established players and favorable government initiatives to drive market 125
TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 126
TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 127
TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 127
10.4.2 JAPAN 128
10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market 128
TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 128
TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 129
TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 129
10.4.3 INDIA 129
10.4.3.1 Rising interest of companies for collaborations to drive market 129
TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 130
TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 131
TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 131
10.4.4 REST OF ASIA PACIFIC 131
TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 132
TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 132
TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 133
10.5 LATIN AMERICA 133
TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION) 133
TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 134
TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 134
TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 135
TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION) 135
10.5.1 BRAZIL 135
10.5.1.1 High HIV prevalence to drive demand for NGS in research 135
TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 136
TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 136
TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 137
10.5.2 MEXICO 137
10.5.2.1 Economic growth and support for infrastructural development to propel market 137
TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 137
TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 138
TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 138
10.5.3 REST OF LATIN AMERICA 138
TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 139
TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 139
TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 140
10.6 MIDDLE EAST & AFRICA 140
10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET 140
TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION) 141
TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION) 141
TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020–2027(USD MILLION) 142
TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020–2027(USD MILLION) 142
11 COMPETITIVE LANDSCAPE 143
11.1 OVERVIEW 143
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 143
FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019–2022 143
11.3 MARKET SHARE ANALYSIS 144
FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021 144
TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION 144
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 145
11.5 COMPETITIVE LEADERSHIP MAPPING 146
11.5.1 TERMINOLOGY/NOMENCLATURE 146
11.5.1.1 Visionary leaders 146
11.5.1.2 Innovators 146
11.5.1.3 Dynamic differentiators 146
11.5.1.4 Emerging companies 146
FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET) 147
FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS) 148
11.6 COMPETITIVE SCENARIO 148
TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES 148
TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS 149
TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS 150
12 COMPANY PROFILES 151
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1 KEY PLAYERS 151
12.1.1 ILLUMINA, INC. 151
TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW 151
FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021 152
TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES 155
TABLE 140 ILLUMINA, INC.: DEALS 156
TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS 157
12.1.2 QIAGEN N.V. 158
TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW 158
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021 159
TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS 163
TABLE 144 QIAGEN N.V.: DEALS 164
12.1.3 PERKINELMER, INC. 166
TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW 166
FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021 167
TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES 168
12.1.4 EUROFINS SCIENTIFIC 169
TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 169
FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021 169
TABLE 148 EUROFINS SCIENTIFIC: DEALS 171
12.1.5 OXFORD NANOPORE TECHNOLOGIES 172
TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW 172
TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES 173
TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS 173
TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS 174
12.1.6 AGILENT TECHNOLOGIES, INC. 175
TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 175
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021 176
12.1.7 BGI GROUP 177
TABLE 154 BGI GROUP: COMPANY OVERVIEW 177
TABLE 155 BGI GROUP: DEALS 177
12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION) 178
TABLE 156 GENEWIZ: COMPANY OVERVIEW 178
TABLE 157 GENEWIZ: SERVICES LAUNCHED 179
12.1.9 HAMILTON COMPANY 180
TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW 180
12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG) 182
TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW 182
12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN) 184
TABLE 160 PSOMAGEN: COMPANY OVERVIEW 184
12.1.12 F. HOFFMANN-LA ROCHE AG 185
TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 185
FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021 186
TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS 187
12.1.13 THERMO FISHER SCIENTIFIC, INC. 188
TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 188
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021 189
TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS 190
12.1.14 TAKARA BIO, INC. 191
TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW 191
FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021 192
12.1.15 PACIFIC BIOSCIENCES 194
TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW 194
FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021 195
12.2 OTHER PLAYERS 198
12.2.1 ZYMO RESEARCH 198
12.2.2 LUCIGEN CORPORATION 198
12.2.3 GENOTYPIC TECHNOLOGY 199
12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX) 199
12.2.5 BECTON, DICKINSON AND COMPANY 200
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX 201
13.1 DISCUSSION GUIDE 201
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
13.3 AVAILABLE CUSTOMIZATION OPTIONS 206
13.4 RELATED REPORTS 207
13.5 AUTHOR DETAILS 208